Parallel Reaction Monitoring-Mass Spectrometry (PRM-MS)-Based Targeted Proteomic Surrogates for Intrinsic Subtypes in Breast Cancer: Comparative Analysis with Immunohistochemical Phenotypes
- 22 November 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 19 (7) , 2643-2653
Abstract
Advances in targeted medications have improved the survival rate of breast cancer patients with molecular marker-positive tumors. To date, immunohistochemistry (IHC) has remained as the standard method for quantifying the markers including HER2, ER, and PR. Nevertheless, IHC-based grading is subjective, because the results depend on trained individuals’ eye rather than numerical quantities. Thus, alternative methods that can account for quantitative levels of markers are gaining popularity, including targeted proteomics by mass spectrometry (MS). However, technical limitations have impeded the application of MS-based protein quantification to pathological FFPE slides that contain low amounts of cross-linked proteins. To challenge this, we developed a parallel reaction monitoring-mass spectrometry (PRM-MS) method to measure the expression levels of breast cancer markers. After developing the method using cell lines, we performed PRM-MS using 51 individuals’ FFPE samples. As a result, we obtained numerical measures of targets, quantifying 13 peptides of 4 markers in a single analysis per sample. The results correlated well with the IHC readings of experienced pathologists. Moreover, the results distinguished a gray zone in HER2 classification, which IHC alone failed to do. This proof-of-concept study demonstrates the application of targeted proteomics in pathologic slides, further supporting the applicability of MS-based approaches in precision medicine.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2017M3C9A5031597)
- Ministry of Trade, Industry and Energy (10045352, 2000134)
- Korea Health Technology R&D project (HI14C2640)
This publication has 46 references indexed in Scilit:
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateJournal of Clinical Oncology, 2018
- Multiplexed, Scheduled, High-Resolution Parallel Reaction Monitoring on a Full Scan QqTOF Instrument with Integrated Data-Dependent and Targeted Mass Spectrometric WorkflowsAnalytical Chemistry, 2015
- The Coming Age of Complete, Accurate, and Ubiquitous ProteomesMolecular Cell, 2013
- Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass SpectrometerMolecular & Cellular Proteomics, 2012
- Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted ProteomicsMolecular & Cellular Proteomics, 2012
- Standardization of Estrogen Receptor Measurement in Breast Cancer Suggests False-Negative Results Are a Function of Threshold Intensity Rather Than Percentage of Positive CellsJournal of Clinical Oncology, 2011
- Breast Cancer Testing Scandal Shines Spotlight on Black Box of Clinical Laboratory TestingJNCI: Journal of the National Cancer Institute, 2008
- Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulationNature Biotechnology, 2006
- Molecular portraits of human breast tumoursNature, 2000
- Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systemsJournal of Clinical Pathology, 2000